Pacific Edge Placement Upsized to NZ$16 Million

PACIFIC EDGE PLACEMENT UPSIZED TO NZ$16 MILLION DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it has successfully raised NZ$16 million of new equity in a placement of new ordinary shares (Placement) — NZ$1 million more than it sought — after Directors resolved to accept over subscriptions.1 The Placement, which was well supported by existing shareholders, was completed on Friday 30 May 2025 and is subject to shareholder approval. It was priced at NZ$0.10 cents per share, a premium to the 20-day volume average weighted price (VWAP) prior to the announcement of the company’s planned ~NZ$20 million equity issue. Pacific Edge is now targeting the opening of a NZ$5 million offer to eligible retail investors by way of a Share Purchase Plan (SPP) at the same NZ$0.10 cents per share offer price in July or early August 2025 (with the ability to accept oversubscriptions). A shareholder meeting to approve the Placement is planned for late July or early August 2025. The Placement and the planned SPP are aimed at ensuring Pacific Edge has additional resources and capacity to capitalize on its recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage of its tests. Medicare coverage of the company’s tests ceased after the ‘Genetic testing for Oncology; Specific Tests’ (L39365) Local Coverage Determination became effective on 24 April 2025. Chairman Chris Gallaher said: “We are delighted with the investor support we have received. The inclusion of Cxbladder in the American Urological Association’s (AUA) new microhematuria guideline in February 2025 is significant and has allowed the company to view the non-coverage determination differently. We are leveraging the important AUA guideline to build on the commercial momentum we have already established, including our plans to regain Medicare coverage.” Pacific Edge Chief Executive Dr Peter Meintjes said: “The robust evidence emerging from our clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests in the US and further afield and represents a significant opportunity in addition to Medicare re-coverage. We are delighted with the strong support we have received from investors to continue to pursue our plans, and we are looking forward to making the same offer to the remainder of our shareholders via the SPP.” Pacific Edge is advised on the equity raise by Cameron Partners (investment banking advisers), Harmos Horton Lusk (legal advisers) and The Project (investor relations and communications advisers). For further information on the detail and timetable of the equity raising please refer to the announcement and presentation dated Thursday 29 May 2025 and released by NZX and ASX on Friday 30 May 2025. Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer. For more information: Investors: Dr Peter Meintjes Chief Executive Pacific Edge P: +64 22 032 1263 Media: Richard Inder The Project P: +64 21 645 643 OVERVIEW Pacific Edge: www.pacificedgedx.com Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. Cxbladder: www.cxbladder.com Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency. Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence. Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.